$HIMS
Hims & Hers Health, Inc.

2020 Q2 Form 10-Q Financial Statement

#000119312520219190 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $35.90M
YoY Change
Cost Of Revenue $10.24M
YoY Change
Gross Profit $25.66M
YoY Change
Gross Profit Margin 71.47%
Selling, General & Admin $14.84M
YoY Change
% of Gross Profit 57.83%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $26.64M
YoY Change
Operating Profit -$979.0K -$16.61K
YoY Change 5795.46%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $35.00K
YoY Change
Pretax Income -$944.0K
YoY Change
Income Tax $37.00K
% Of Pretax Income
Net Earnings -$981.0K -$16.61K
YoY Change 5807.5%
Net Earnings / Revenue -2.73%
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share -$0.03
COMMON SHARES
Basic Shares Outstanding 35.33M shares
Diluted Shares Outstanding 35.33M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.400M
YoY Change
Cash & Equivalents $1.386M
Short-Term Investments
Other Short-Term Assets $100.0K
YoY Change
Inventory
Prepaid Expenses $90.20K
Receivables
Other Receivables
Total Short-Term Assets $1.476M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $204.7M
YoY Change
Other Assets $500.0K
YoY Change
Total Long-Term Assets $204.7M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.476M
Total Long-Term Assets $204.7M
Total Assets $206.2M $536.3K
YoY Change 38347.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.66K $21.98K
YoY Change -1.47%
Accrued Expenses $535.9K $449.1K
YoY Change 19.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $100.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.168M $527.9K
YoY Change 121.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.200M
YoY Change
Total Long-Term Liabilities $7.200M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.168M $527.9K
Total Long-Term Liabilities $7.200M $0.00
Total Liabilities $8.361M $500.0K
YoY Change 1572.29%
SHAREHOLDERS EQUITY
Retained Earnings $2.395M -$16.61K
YoY Change -14519.54%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$138.9M $0.00
YoY Change
Total Liabilities & Shareholders Equity $206.2M $536.3K
YoY Change 38347.19%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$981.0K -$16.61K
YoY Change 5807.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$90.00K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -90.00K 0.000
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -90.00K 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$90.00K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
oacu Regulatory Withdrawal
RegulatoryWithdrawal
325000
CY2020Q2 us-gaap Cash
Cash
1400000
CY2020Q2 oacu Working Capital
WorkingCapital
308000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q2 us-gaap Assets
Assets
206200737
CY2019Q4 us-gaap Assets
Assets
204765183
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
535852
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
478577
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
21656
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18475
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1167702
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
979394
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2604910
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3852147
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2394508
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1147262
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5000005
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
206200737
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5000009
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1334022
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5000001
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
8394
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
57275
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204765183
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
123634
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-86776
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
370417
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16606
us-gaap Net Income Loss
NetIncomeLoss
1247246
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16606
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3181
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-124809
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-124809
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1510341
CY2019Q3 oacu Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P185D
CY2019Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2019Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
25000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1385532
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
90200
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
147500
CY2020Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
204725005
CY2019Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
203107342
CY2020Q2 oacu Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
114839
CY2019Q4 oacu Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
54839
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
495355
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
427503
CY2020Q2 oacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2019Q4 oacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2020Q2 oacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2019Q4 oacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2020Q2 us-gaap Liabilities
Liabilities
8361452
CY2019Q4 us-gaap Liabilities
Liabilities
8173144
CY2020Q2 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
192839280
CY2019Q4 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
191592030
CY2019Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
11900000
CY2019Q2 oacu Percentage Of Founder Shares On Outstanding Shares
PercentageOfFounderSharesOnOutstandingShares
0.20
oacu Common Stock Shares Resale Or Transfer Share Price Threshold
CommonStockSharesResaleOrTransferSharePriceThreshold
12.00
oacu Advances From Related Party Agreed Amount
AdvancesFromRelatedPartyAgreedAmount
300000
CY2019Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
CY2019Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12214
CY2019Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4392
CY2020Q2 oacu Advances From Related Party
AdvancesFromRelatedParty
62000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin: 6pt 0in 0.0001pt; text-indent: 4%; font-family: &quot;times new roman&quot;, serif; text-align: justify;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the<div style="letter-spacing: 0px; top: 0px;;display:inline;"> unaudited condensed</div> financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting <div style="letter-spacing: 0px; top: 0px;;display:inline;">periods</div>. Making estimates requires management to exercise significant judgment.&#160;It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events.&#160;Accordingly, the actual results could differ from those estimates. </div></div></div></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
oacu Common Stock Conversion Description
CommonStockConversionDescription
20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity- linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans.
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Oaktree Acquisition Corp.
dei Entity Central Index Key
EntityCentralIndexKey
0001773751
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q2 oacu Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
-436852
CY2019Q2 oacu Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
-17587
CY2019Q2 oacu Offering Costs Paid By Sponsor In Exchange For Issuance Of Classb Ordinary Shares
OfferingCostsPaidBySponsorInExchangeForIssuanceOfClassbOrdinaryShares
-25000
CY2019Q3 oacu Business Combination Requisites To Be Satisfied
BusinessCombinationRequisitesToBeSatisfied
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
CY2019Q3 oacu Business Combination Covenants To Proceed With Business Combination
BusinessCombinationCovenantsToProceedWithBusinessCombination
In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination.
CY2019Q3 oacu Description Of Results For Non Compliance With Business Combination
DescriptionOfResultsForNonComplianceWithBusinessCombination
The Company&#8217;s Sponsor, officers and directors (the &#8220;initial shareholders&#8221;) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company&#8217;s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or July 22, 2021
CY2020Q2 us-gaap Assets Current
AssetsCurrent
1475732
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1657841
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-123634
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
36858
CY2020Q1 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
-1334030
us-gaap Investment Income Interest
InvestmentIncomeInterest
1617663
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-57300
oacu Increase Decrease In Accrued Expensed Related Party
IncreaseDecreaseInAccruedExpensedRelatedParty
-60000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
67852
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
oacu Cumulative Earnings For Beginning Of The Investment
CumulativeEarningsForBeginningOfTheInvestment
3500000
oacu Annual Threshold Limit Regulatory Withdrawal
AnnualThresholdLimitRegulatoryWithdrawal
325000
oacu Proceeds From Issuance Of Founder Shares
ProceedsFromIssuanceOfFounderShares
25000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-370417
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16606
us-gaap Investment Income Interest
InvestmentIncomeInterest
1617663
CY2020Q2 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
86780
CY2020Q2 oacu Founder Shares Subject To Redemption
FounderSharesSubjectToRedemption
656250
oacu Change In Value Of Class A Ordinary Shares Subject To Possible Redemption
ChangeInValueOfClassAOrdinarySharesSubjectToPossibleRedemption
1247250
CY2020Q2 oacu Working Capital Loan
WorkingCapitalLoan
0
CY2019Q2 oacu Offering Costs Paid By Related Parties
OfferingCostsPaidByRelatedParties
56883
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000

Files In Submission

Name View Source Status
0001193125-20-219190-index-headers.html Edgar Link pending
0001193125-20-219190-index.html Edgar Link pending
0001193125-20-219190.txt Edgar Link pending
0001193125-20-219190-xbrl.zip Edgar Link pending
d70642d10q.htm Edgar Link pending
d70642dex311.htm Edgar Link pending
d70642dex312.htm Edgar Link pending
d70642dex321.htm Edgar Link pending
d70642dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
oacu-20200630.xml Edgar Link completed
oacu-20200630.xsd Edgar Link pending
oacu-20200630_cal.xml Edgar Link unprocessable
oacu-20200630_def.xml Edgar Link unprocessable
oacu-20200630_lab.xml Edgar Link unprocessable
oacu-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending